Trial Profile

DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin (trastuzumab) and Perjeta (pertuzumab) plus Kisqali (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Ribociclib (Primary) ; Trastuzumab (Primary) ; Anastrozole; Capecitabine; Docetaxel; Eribulin; Exemestane; Fulvestrant; Goserelin; Letrozole; Leuprorelin; Paclitaxel; Tamoxifen; Vinorelbine
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Adverse reactions
Acronyms DETECT V; DETECT V/CHEVENDO

03 Jun 2024 Planned End Date changed from 1 Nov 2024 to 31 Jan 2025.
03 Jun 2024 Planned primary completion date changed from 1 Sep 2024 to 31 Jan 2025.
03 Jun 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com